Silver Book Fact

Pioglitazone associated with relative risk reduction in recurrent stroke

The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative risk reduction in recurrent stroke.

Wilcox, Robert, Marie-Germaine Bousser, John Betteridge, Guntram Schernthaner, Valdis Pirags, Stuart Kupfer, and John Dormandy; for the PROactive Investigators. Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04). Stroke. 2007; 38(3): 865-73. http://stroke.ahajournals.org/cgi/content/short/38/3/865

Reference

Title
Effects of Pioglitazone in Patients with Type 2 Diabetes with or without Previous Stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macro Vascular Events 04)
Publication
Stroke
Publication Date
2007
Authors
Wilcox, Robert, Marie-Germaine Bousser, John Betteridge, Guntram Schernthaner, Valdis Pirags, Stuart Kupfer, and John Dormandy; for the PROactive Investigators
Volume & Issue
Volume 38, Issue 3
Pages
865-73
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The greater use of medications and revascularization would provide approximately a 17% reduction in 2 year mortality combined.  
  • Direct thrombin inhibitor reduced relative risk of venous thromboembolism
    An investigational direct thrombin inhibitor reduced relative risk of venous thromboembolism after total hip replacement surgery by 65.7%—compared to a currently available treatment.  
  • Following the current path, heart disease cases will increase by 41.1% between 2003 and 2023. If an alternative path is taken, there will be 34.6% (9.4 million) fewer heart disease…  
  • Following the current path, pulmonary condition cases will increase by 31.3% between 2003 and 2023. If an alternative path is taken, there will be 9.1% fewer pulmonary condition cases.  
  • Use of antihypertensive therapies avoided an estimated $10.7 billion in 2002 direct medical costs as a result of fewer strokes. They also avoided an estimated $5.8 billion in 2002…